A
29.68
1.07 (3.73%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Alto Neuroscience, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | 3.4 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 4.0 |
| 技术平均移动指标 参考 | 2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×0.79 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.4% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | -1.0 |
| 最终评分 | 0.94 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 7.48% |
| 机构持股比例 | 77.52% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Alpha Wave Global, Lp | 30 Jun 2026 | 3,707,757 |
| Commodore Capital Lp | 30 Jun 2026 | 2,723,196 |
| Perceptive Advisors Llc | 30 Jun 2026 | 1,609,893 |
| Spruce Street Capital Lp | 30 Jun 2026 | 1,353,047 |
| Vivo Capital, Llc | 30 Jun 2026 | 1,208,858 |
| Armistice Capital, Llc | 30 Jun 2026 | 864,000 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 850,000 |
| Vestal Point Capital, Lp | 30 Jun 2026 | 785,000 |
该时间范围内无数据。
该时间范围内无数据。
投资组合